Agomelatine: A New Antidepressant
Author Information
Author(s): Manikandan S
Primary Institution: Indira Gandhi Medical College and Research Institute
Hypothesis
Can agomelatine effectively treat major depression?
Conclusion
Agomelatine is a novel antidepressant that shows potential but requires further testing to fully understand its real-world effects.
Supporting Evidence
- Agomelatine is an agonist at melatonergic MT1 and MT2 receptors and an antagonist at serotonin 5HT2C receptor.
- Short-term trials showed significant improvement in depression symptoms compared to placebo.
- A long-term trial indicated a lower cumulative relapse rate for agomelatine.
- Agomelatine has minimal effects on sexual function and is not addictive.
Takeaway
Agomelatine is a new medicine that helps people with depression by fixing their sleep patterns and mood without making them feel sleepy during the day.
Methodology
The study involved short-term and long-term clinical trials measuring the efficacy and safety of agomelatine in patients with major depression.
Limitations
The trials involved only a few hundred patients and had a maximum follow-up of 24 weeks.
Participant Demographics
Patients with major depression or bipolar II depression.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website